Siena – As reported today by Il Sole 24 Ore, the Australian company Seqirus invests in Siena for the development of influenza vaccines. With a note, Vismederi, a company incubated in Tuscany Life Science, Siena, active in the field of applied research and services, announces the signing of a collaboration agreement with the company of the CSL group, world leader in the production of vaccines.
“The project – reads the note – provides for a local investment by the Australian company of several million “which will be used to finance the study and testing in Siena of new-generation influenza vaccines that will then be produced by Seqirus in American and British sites. Thanks to this agreement – concludes the company – “Siena remains active in the field of influenza vaccination”.
